We combine cancer genetics and next-generation sequencing to help researchers identify molecular alterations responsible for how cancers grow, invade, and metastasize, or how they are sensitive or resistant to various therapies.
Whole genome sequencing germline analysis to identify cancer predisposition genes.
CancerXOME™ analysis of patient derived xenograft (PGDx) models to study genetic changes associated with drug response in an animal model.
Application of MET assay to identify rearrangements and amplifications in plasma for retrospective study.
Using CancerXOME™ to develop a targeted approach to identify key genetic markers of response in Phase II and II clinical trials.
Customized plasma assay for rapid turnaround NGS-based assays. Available for global implementation and execution.